We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.
- Authors
Moe, Sharon M; Chertow, Glenn M; Coburn, Jack W; Quarles, L Darryl; Goodman, William G; Block, Geoffrey A; Drüeke, Tilman B; Cunningham, John; Sherrard, Donald J; McCary, Laura C; Olson, Kurt A; Turner, Stewart A; Martin, Kevin J
- Abstract
The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (NKF-K/DOQItrade mark) has established guidelines for treatment of secondary hyperparathyroidism (HPT). The ability of cinacalcet HCl (Sensipartrade mark) treatment to improve achievement of target levels of parathyroid hormone (PTH), calcium, phosphorus, and calcium-phosphorus product (Ca x P) was investigated in subjects on dialysis with secondary HPT.
- Publication
Kidney international, 2005, Vol 67, Issue 2, p760
- ISSN
0085-2538
- Publication type
Journal Article
- DOI
10.1111/j.1523-1755.2005.67139.x